Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469564 | 1.00 | PTGS2 (0.51) | PTGS2PTGS1CYP1A2CYP2C19TDP1 | |
| SCHEMBL4467387 | 0.90 | POLB (0.52) | PTGS2PTGS1TDP1POLBMEN1 | |
| SCHEMBL4485374 | 0.90 | POLB (0.52) | PTGS2PTGS1TDP1POLBMEN1 | |
| SCHEMBL4464157 | 0.89 | MAPT (0.45) | PTGS2PTGS1CYP1A2CYP2C19TDP1 | |
| SCHEMBL4464159 | 0.89 | MAPT (0.45) | PTGS2PTGS1CYP1A2CYP2C19TDP1 | |
| SCHEMBL4482399 | 0.88 | ALDH1A1 (0.42) | PTGS2PTGS1TDP1POLBGSK3B | |
| SCHEMBL4482406 | 0.88 | ALDH1A1 (0.42) | PTGS2PTGS1TDP1POLBGSK3B | |
| SCHEMBL4475965 | 0.87 | PTGS1 (0.53) | PTGS2PTGS1TDP1POLBMEN1 | |
| SCHEMBL4475955 | 0.87 | PTGS1 (0.53) | PTGS2PTGS1TDP1POLBMEN1 | |
| SCHEMBL4479600 | 0.83 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | PTGS2 4182/4885PTGS1 4101/4885CYP1A2 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.